Worsening Autoimmune Neutropenia After Stopping Ibrutinib in a Patient With Chronic Lymphocytic Leukemia: Case Report and Review of Literature

Natalie Rosen, BA, Thomas Klumpp, MD, and Sameh Gaballa, MD, MSc

INTRODUCTION

Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic leukemia occurring in 5-10% of patients during the course of their disease. Autoimmune hemolytic anemia (AIHA) constitutes the highest prevalence (5-10%) of CLL-associated AIC followed by idiopathic thrombocytopenic purpura (ITP) (2-5%), pure red cell aplasia (PRCA) (<1%), and autoimmune neutropenia (AIN) (<1%). The prevalence of AIN, however, may in fact be higher than reported due to a lack of awareness of the condition and difficulty in its diagnosis. Despite its rarity, autoimmune neutropenia can be a significant clinical challenge in patients with CLL and can increase the risk of infectious complications. Thus, the prompt diagnosis and resolution of CLL-associated AIN is essential to the management of these patients.

Ibrutinib is a selective inhibitor of Bruton tyrosine kinase and induces a durable response in patients with CLL. The activity of ibrutinib in CLL-associated AIC is largely unknown as pivotal clinical trials excluded patients with AIC. We report a case of a patient with CLL who experienced worsening of AIN after discontinuing ibrutinib therapy. Given its immune modulatory effects, these findings suggest ibrutinib may have a role in controlling AIN in patients with CLL.

CASE PRESENTATION

This is a 72 year-old female who was diagnosed with CLL in early 2000 after presenting with progressive left cervical lymphadenopathy. Prognostic markers of CLL were not evaluated at the time of diagnosis. She was treated with fludarabine and rituximab and achieved a complete response. She continued on active surveillance for five years until she had evidence of disease recurrence.

She was treated with single agent rituximab in 2005 and then rituximab-bendamustine in 2009 and achieved complete remission. In 2012, she had evidence of disease progression with diffuse adenopathy and a biopsy was performed to rule out disease transformation. FISH studies at that time revealed trisomy 12 and 17p deletion. The patient did not wish to undergo further chemotherapy and instead was treated with high dose methylprednisolone with rituximab followed by lenalidomide. Her CLL was controlled on this regimen, however, she developed thrombocytopenia (platelet count of 46,000 per cubic millimeter), leg heaviness, and fatigue from the lenalidomide and it was stopped in June 2014. Three weeks after stopping lenalidomide, she developed incidental neutropenia with an absolute neutrophil count (ANC) of 900 cells/µL. Due to a lack of constitutional symptoms, she was not treated for her neutropenia and her counts improved spontaneously.

In September 2014, she was started on ibrutinib for disease progression and achieved a partial response. However, by August 2017 she noted increased pelvic lymphadenopathy and leukocytosis consistent with progressive disease. Genome sequencing studies revealed the presence of a BTKI mutation (C481S) conferring resistance to ibrutinib as well as an IGH-BCL2 rearrangement, ATM R248, and NOTCH1. Ibrutinib was discontinued in November 2017 and venetoclax was initiated. Subsequently, her ANC began declining which was initially thought to be a related side effect of venetoclax. However, despite multiple dose reductions and interrupting venetoclax for 7 weeks, her ANC remained below 500 cells/µL. The differential diagnosis at this time included myelodysplastic syndrome and autoimmune neutropenia. Therefore, a bone marrow biopsy was performed which revealed only 10% involvement with CLL and no evidence of myelodysplasia. Moreover, there was evidence of myeloid maturation arrest further suggesting autoimmunity as her etiology of neutropenia. She received oral steroids and rituximab which resulted in a rapid resolution of her neutropenia. However, due to a decreasing ANC, tbo-filgastrim was added to her regimen every 10 days. Venetoclax was restarted, in conjunction with tbo-filgastrim, and her ANC continued to be maintained above 1000 cells/µL. She has remained stable on this therapeutic regimen for almost one year.
using pooled data from four clinical trials which found that AIC therapy was discontinued in 86% of patients after a median of 4.7 months of initiating ibrutinib. Similarly, our group previously reported a case of CLL induced ITP that was successfully controlled with ibrutinib and rapidly flared after brief ibrutinib discontinuation. This also mirrors another case reported by Molica et al where a patient with CLL-associated AIHA experienced exacerbation of hemolysis twice after stopping ibrutinib. Conversely, some reports suggest that ibrutinib may initially and transiently worsen AIHA in patients with CLL, but with continued use, it may ultimately control AICs.

Our report suggests a role for ibrutinib in controlling CLL-associated AICs including AIN. Ibrutinib may be a new therapeutic option for AIN patients with concomitant treatment indications for their underlying CLL. This case also illustrates that some patients may develop an AIN flare after stopping ibrutinib.

DISCUSSION
We present a case of worsening AIN after stopping ibrutinib that was successfully managed with steroids, rituximab, and infrequent growth factor support. AIN is relatively uncommon in patients with CLL, but its presence should be suspected if other causes of neutropenia are ruled out. The pathogenesis of AICs in patients with CLL is not well understood and is possibly related to immune dysregulation including ineffective regulatory T-cell function. Additionally, humoral immunity can also be impacted as CLL cells may process cryptic antigens differently from normal B cells and thus present a peptide for which there is no immunological tolerance. Lastly, AICs in patients with CLL can also be drug-induced (purine analogs and alkylating agents).

The role of ibrutinib in AIN is controversial and patients with AICs were largely excluded from pivotal ibrutinib clinical trials. In a retrospective analysis of 301 CLL patients treated with ibrutinib at Ohio State University Cancer Center, six patients developed treatment-emergent AICs. However, these episodes of AIC occurred within 6 days to 23 months after ibrutinib initiation and thus did not appear to be temporally linked to the therapy. Furthermore, 25% of these patients had a past history of AICs and 7% were already receiving active therapy for AIC at the time of ibrutinib initiation.

In the phase 3 RESONATE-1 study, which compared ibrutinib vs. ofatumumab in previously treated CLL/SLL patients, ibrutinib did not precipitate recurrent AICs in patients with CLL who had a history of autoimmune complications. In fact, ibrutinib may play a therapeutic role in the prevention and treatment of AICs in patients with CLL. This was illustrated in one retrospective study using pooled data from four clinical trials which found that AIC therapy was discontinued in 86% of patients after a median of 4.7 months of initiating ibrutinib. Similarly, our group previously reported a case of CLL induced ITP that was successfully controlled with ibrutinib and rapidly flared after brief ibrutinib discontinuation. This also mirrors another case reported by Molica et al where a patient with CLL-associated AIHA experienced exacerbation of hemolysis twice after stopping ibrutinib. Conversely, some reports suggest that ibrutinib may initially and transiently worsen AIHA in patients with CLL, but with continued use, it may ultimately control AICs.

Our report suggests a role for ibrutinib in controlling CLL-associated AICs including AIN. Ibrutinib has a variety of mechanisms which can influence the immune system and potentially influence AICs. It inhibits interleukin-2-inducible kinase (ITK), which decreases the response of autoreactive T cells and can also modulate cytokine levels to promote a shift from a Th-2 towards a Th-1 mediated immune response. Additionally, ibrutinib inhibits B-cell receptor signaling which can inhibit the ability of B cells to respond to produce pathologic antibodies. Literature on this notion is currently conflicting and further research is needed to better elucidate the relationship between ibrutinib, CLL, and AICs.

CLL-associated AICs, such as AIN, are common throughout the course of disease. Steroids, immunosuppressive, or granulocyte stimulating therapy in the case of AIN are the current standard treatment options. Ibrutinib may be a new therapeutic option for AIN patients with concomitant treatment indications for their underlying CLL. This case also illustrates that some patients may develop an AIN flare after stopping ibrutinib.
REFERENCES


